Ubs Group Ag Cns Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.26 - $1.05 $949 - $3,835	-3,653 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$0.7 - $1.54 $2,557 - $5,625	3,653 New	3,653 $3,000
Q3 2021 Nov 15, 2021	SELL	$1.4 - $1.98 $6,546 - $9,258	-4,676 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$1.71 - $2.42 $5,670 - $8,024	3,316 Added 243.82%	4,676 $9,000
Q1 2021 May 12, 2021	BUY	$1.72 - $4.18 $2,339 - $5,684	1,360 New	1,360 $3,000
Q4 2020 Feb 11, 2021	SELL	$1.68 - $2.89 $6,652 - $11,444	-3,960 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$1.69 - $2.64 $6,692 - $10,454	3,960 New	3,960 $7,000
Q2 2020 Jul 31, 2020	SELL	$2.0 - $3.7 $3,860 - $7,141	-1,930 Closed	0 $0
Q1 2020 May 01, 2020	BUY	$1.45 - $4.99 $2,798 - $9,630	1,930 New	1,930 $4,000

100

Ticker CNSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,032,500
Market Cap $4.4M
Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme....

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.